Nova Eye Medical Ltd
ASX:EYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nova Eye Medical Ltd
Cash from Operating Activities
Nova Eye Medical Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nova Eye Medical Ltd
ASX:EYE
|
Cash from Operating Activities
-AU$6.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Cash from Operating Activities
AU$7.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
23%
|
|
|
Cochlear Ltd
ASX:COH
|
Cash from Operating Activities
AU$264.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash from Operating Activities
-AU$6.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-17%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Cash from Operating Activities
AU$20.4m
|
CAGR 3-Years
94%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash from Operating Activities
-AU$8.9m
|
CAGR 3-Years
-122%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Nova Eye Medical Ltd
Glance View
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).
See Also
What is Nova Eye Medical Ltd's Cash from Operating Activities?
Cash from Operating Activities
-6.2m
AUD
Based on the financial report for Dec 31, 2025, Nova Eye Medical Ltd's Cash from Operating Activities amounts to -6.2m AUD.
What is Nova Eye Medical Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
10%
Over the last year, the Cash from Operating Activities growth was 15%. The average annual Cash from Operating Activities growth rates for Nova Eye Medical Ltd have been 10% over the past three years .
